DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for cardiac valvular defect, developmental — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCardiac valvular defect, developmental maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cardiac valvular defect, developmental is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phospholipase D1 (PLD1) — PLD1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6OHR · 3.2 Å · ligand 4-fluoro-N-{(2S)-1-[(5R)-5-(3-fluorophenyl)-2-oxo-1-oxa-3,9-diazaspiro[5.5]undecan-9-yl]propan-2-yl}benzamide (MKG). Experimental structure, not a prediction.
What the evidence adds up to
The first abstract, from 2016, states that valvular heart disease can be congenital, acquired, or both, and that acquired disease may be rheumatic or nonrheumatic. It provides no data on treatment or outcomes. The second abstract, from 2024, notes that many valvular heart diseases are acquired later in life but that an important genetic component exists, particularly in mitral valve prolapse and bicuspid aortic valve. It mentions that these conditions can arise from genetic syndromes such as Marfan disease or Turner syndrome, or appear in non-syndromic, familial, or sporadic forms. The abstract calls for identification of new genes and molecular pathways but reports no clinical trial results, no drug interventions, and no survival or response rates. The third abstract, from 1993, states that advances in diagnostic and surgical techniques have improved survival for patients with congenital heart defects or acquired valvular heart disease, and that heart-transplant survival has also improved. It offers no drug-specific data and no quantitative outcomes.
No abstract in this set reports any drug tested for developmental cardiac valvular defect. There is no mention of a drug being repurposed, no clinical trial, no animal model, and no molecular target linked to a specific compound. The 2024 review explicitly states that novel therapeutic strategies are still needed, and that the identification of genetic contributors is at an early stage.
What is missing is any clinical or preclinical evidence for a drug that could alter the course of developmental valvular disease. There are no trials, no patient stratification by genotype, no funding directed at drug repurposing for this specific defect, and no data on whether existing drugs for acquired valve disease would have any effect on congenital forms.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Thoracic Disease · 2016 · 12 citations · open access
Growing importance of valvular heart disease in the elderly
AbstractValvular heart disease (VHD) which defines as structural or functional abnormality of cardiac valve, is a major health problem and presence of severe VHD may be the important cause of disability, reduced quality of life, cardiac dysfunction and premature mortality from cardiovascular disease. The etiology of VHD may be congenital, acquired, or both. Acquired VHD may be rheumatic or nonrheumatic origin.
Reviews in Cardiovascular Medicine · 2024 · 4 citations · open access
Valvulopathies and Genetics: Where are We?
AbstractValvulopathies are among the most common cardiovascular diseases, significantly increasing morbidity and mortality. While many valvular heart diseases are acquired later in life, an important genetic component has been described, particularly in mitral valve prolapse and bicuspid aortic valve. These conditions can arise secondary to genetic syndromes such as Marfan disease (associated with mitral valve prolapse) or Turner syndrome (linked to the bicuspid aortic valve) or may manifest in a non-syndromic form. When cardiac valve disease is the primary cause, it can appear in a familial clustering or sporadically, with a clear genetic component. The identification of new genes, regulatory elements, post-transcriptional modifications, and molecular pathways is crucial to identify at-risk familial carriers and for developing novel therapeutic strategies. In the present review we will discuss the numerous genetic contributors of heart valve diseases.
Current Opinion in Anaesthesiology · 1993 · 0 citations
Valvular and congenital heart disease
AbstractAdvances in diagnostic and surgical techniques have made significant contributions to improved survival of patients with congenital heart defects or acquired valvular heart disease. The survival rate of heart-transplant patients has also improved dramatically in recent years. As a result, many of these patients will present for non-cardiac surgery. The implications and potential risks associated with this patient population are reviewed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
